Search research articles
Contact Us
Filters
Showing results (11-20 of 69) with videos related to
Page
of 7
Sort By:
Breast Cancer Research and Treatment
|
February 27, 2020
Evaluating the clinical effectiveness and safety of various HER2-targeted regimens after prior taxane/trastuzumab in patients with previously treated, unresectable, or metastatic HER2-positive breast cancer: a systematic review and network meta-analysis
Noman Paracha, Adriana Reyes, Véronique Diéras, et al.
Nucleic Acids Research
|
March 15, 2011
GPHMM: an integrated hidden Markov model for identification of copy number alteration and loss of heterozygosity in complex tumor samples using whole genome SNP arrays
Ao Li, Zongzhi Liu, Kimberly Lezon-Geyda, et al.
Cancer Research
|
November 4, 2005
HIN-1, an inhibitor of cell growth, invasion, and AKT activation
Ian Krop, Michele Taylor Parker, Noga Bloushtain-Qimron, et al.
JAMA Oncology
|
January 13, 2022
Aiming at a Tailored Cure for ERBB2-Positive Metastatic Breast Cancer: A Review
Paolo Tarantino, Giuseppe Curigliano, Heather A Parsons, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 22, 2010
Ethics of mandatory research biopsy for correlative end points within clinical trials in oncology
Jeffrey Peppercorn, Iuliana Shapira, Deborah Collyar, et al.
Cancer Research
|
May 3, 2003
Lack of HIN-1 methylation in BRCA1-linked and "BRCA1-like" breast tumors
Ian Krop, Paula Maguire, Jaana Lahti-Domenici, et al.
Cancer Research
|
December 17, 2005
A putative role for psoriasin in breast tumor progression
Ian Krop, Annette März, Hanna Carlsson, et al.
JAMA Oncology
|
June 30, 2018
Tucatinib Combined With Ado-Trastuzumab Emtansine in Advanced ERBB2/HER2-Positive Metastatic Breast Cancer: A Phase 1b Clinical Trial
Virginia F Borges, Cristiano Ferrario, Nathalie Aucoin, et al.
Breast Cancer Research and Treatment
|
December 25, 2014
Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer
Sara Tolaney, Howard Burris, Elaina Gartner, et al.
Investigational New Drugs
|
February 14, 2009
A phase II study of oral enzastaurin in patients with metastatic breast cancer previously treated with an anthracycline and a taxane containing regimen
Lida Mina, Ian Krop, Robin T Zon, et al.
Page
of 7
Search research articles
Search
Showing results (11-20 of 69) with videos related to
Sort By:
Page
of 7
Breast Cancer Research and Treatment
|
February 27, 2020
Evaluating the clinical effectiveness and safety of various HER2-targeted regimens after prior taxane/trastuzumab in patients with previously treated, unresectable, or metastatic HER2-positive breast cancer: a systematic review and network meta-analysis
Noman Paracha, Adriana Reyes, Véronique Diéras, et al.
Nucleic Acids Research
|
March 15, 2011
GPHMM: an integrated hidden Markov model for identification of copy number alteration and loss of heterozygosity in complex tumor samples using whole genome SNP arrays
Ao Li, Zongzhi Liu, Kimberly Lezon-Geyda, et al.
Cancer Research
|
November 4, 2005
HIN-1, an inhibitor of cell growth, invasion, and AKT activation
Ian Krop, Michele Taylor Parker, Noga Bloushtain-Qimron, et al.
JAMA Oncology
|
January 13, 2022
Aiming at a Tailored Cure for ERBB2-Positive Metastatic Breast Cancer: A Review
Paolo Tarantino, Giuseppe Curigliano, Heather A Parsons, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 22, 2010
Ethics of mandatory research biopsy for correlative end points within clinical trials in oncology
Jeffrey Peppercorn, Iuliana Shapira, Deborah Collyar, et al.
Cancer Research
|
May 3, 2003
Lack of HIN-1 methylation in BRCA1-linked and "BRCA1-like" breast tumors
Ian Krop, Paula Maguire, Jaana Lahti-Domenici, et al.
Cancer Research
|
December 17, 2005
A putative role for psoriasin in breast tumor progression
Ian Krop, Annette März, Hanna Carlsson, et al.
JAMA Oncology
|
June 30, 2018
Tucatinib Combined With Ado-Trastuzumab Emtansine in Advanced ERBB2/HER2-Positive Metastatic Breast Cancer: A Phase 1b Clinical Trial
Virginia F Borges, Cristiano Ferrario, Nathalie Aucoin, et al.
Breast Cancer Research and Treatment
|
December 25, 2014
Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer
Sara Tolaney, Howard Burris, Elaina Gartner, et al.
Investigational New Drugs
|
February 14, 2009
A phase II study of oral enzastaurin in patients with metastatic breast cancer previously treated with an anthracycline and a taxane containing regimen
Lida Mina, Ian Krop, Robin T Zon, et al.
Page
of 7